Trials / Unknown
UnknownNCT03260192
Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
Detailed description
Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
Conditions
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2017-08-24
- Last updated
- 2024-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03260192. Inclusion in this directory is not an endorsement.